Drugs and Devices

FDA approves new melanoma treatments

  • On Oct. 28, the U.S. Food and Drug Administration (FDA) expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. Read more.
  • On Oct. 27, the FDA approved Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes. Read more.

Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares